A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy

Nephrology Dialysis Transplantation

Volumn 29, Issue 8, 2014, Pages 1570-1577

  Hladunewich, Michelle A ^a   Cattran, Daniel ^a   Beck, Laurence H ^b   Odutayo, Ayodele ^a   Sethi, Sanjeev ^c   Ayalon, Rivka ^b   Leung, Nelson ^c   Reich, Heather ^a   Fervenza, Fernando C ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

ACTH (H.P. Acthar Gel); membranous nephropathy; nephrotic syndrome

Indexed keywords

ALBUMIN; CHOLESTEROL; CORTICOTROPIN; H.P. ACTHAR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2 RECEPTOR; UNCLASSIFIED DRUG;

ACNE; ADULT; ARTICLE; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IDIOPATHIC MEMBRANOUS NEPHROPATHY; INJECTION SITE CONTUSION; INSOMNIA; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACTH (H.P. ACTHAR® GEL); MEMBRANOUS NEPHROPATHY; NEPHROTIC SYNDROME;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84905027151     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu069     Document Type: Article

References (31)

1. Swaminathan S, Leung N, Lager DJ et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: A 30-year renal biopsy study. Clin J Am Soc Nephrol 2006; 1: 483-487
2. MacTier R, Boulton Jones JM, Payton CD et al. The natural history of membranous nephropathy in the West of Scotland. Q J Med 1986; 60: 793-802
3. Noel LH, Zanetti M, Droz D et al. Long-Term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 1979; 66: 82-90
4. Zucchelli P, Ponticelli C, Cagnoli L et al. Long-Term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 1987; 2: 73-78
5. Davison AM, Cameron JS, Kerr DN et al. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 1984; 22: 61-67
6. Cattran DC, Pei Y, Greenwood CM et al. Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 1997; 51: 901-907
7. Barbour SJ, Greenwald A, Djurdjev O et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012; 81: 190-195
8. Polanco N, Gutierrez E, Covarsi A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704
9. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2: 186-197
10. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 2012; 8: 122-128
11. Lindskog A, Ebefors K, Johansson ME et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010; 21: 1290-1298
12. Berg AL, Hansson P, Nilsson-Ehle P. ACTH 1-24 decreases hepatic lipase activities and low density lipoprotein concentrations in healthy men. J Intern Med 1991; 229: 201-203
13. Berg AL, Nilsson-Ehle P. Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies in vivo and in vitro. Metabolism 1994; 43: 90-97
14. Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-Treated hyperlipemic patients with kidney disease. Kidney Int 1996; 50: 538-542
15. Arnadottir M, Berg AL, Dallongeville J et al. Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients. Kidney Int 1997; 52: 1651-1655
16. Hofstra JM, Beck LH, Jr, Beck DM et al. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6: 1286-1291
17. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1-266
18. Clinical Practice Guidelines for Treatment of Dyslipidemia. Am J Kidney Dis 2003; 41(4 Suppl 3): I-IV, S1-91
19. Beck LH, Jr, Bonegio RG, Lambeau G et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
20. Lauson HD, Forman CW, Mc NH et al. The effect of corticotropin (ACTH) on glomerular permeability to albumin in children with the nephrotic syndrome. J Clin Invest 1954; 33: 657-664
21. Soshea JW, Farnsworth EB. Serum lipid analysis in the nephrotic syndrome under ACTH administration. J Lab Clin Med 1951; 38: 414-419
22. Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004; 19: 1305-1307
23. Ponticelli C, Passerini P, Salvadori M et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47: 233-240
24. Rauen T, Michaelis A, Floege J et al. Case series of idiopathic membranous nephropathy with long-Term beneficial effects of ACTH peptide 1-24. Clin Nephrol 2009; 71: 637-642
25. Bomback AS, Canetta PA, Beck LH, Jr. et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: A prospective trial. Am J Nephrol 2012; 36: 58-67
26. Kim S, Chin HJ, Na KY et al. Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy. Nephron Clin Pract 2011; 117: C253-c258
27. Beck LH, Jr, Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1543-1550
28. Catania A, Lonati C, Sordi A et al. The melanocortin system in control of inflammation. ScientificWorldJournal 2010; 10: 1840-1853
29. Ghiggeri GM, Bruschi M, Candiano G et al. Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int 2002; 62: 2184-2194
30. Yamada K, Hori Y, Hanafusa N et al. Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Int 2001; 59: 137-146
31. Rastaldi MP, Candiano G, Musante L et al. Glomerular clusterin is associated with PKC-Alpha/beta regulation and good outcome of membranous glomerulonephritis in humans. Kidney Int 2006; 70: 477-485